prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - tüve a / viet nam / 1194/2004 (h5n1) gripiviiruse pinnaantigeenid (hemaglutiniin ja neuraminidaas) - influenza, human; immunization; disease outbreaks - vaktsiinid - aktiivne immuniseerimine gripiviiruse a viiruse h5n1 alatüübi vastu. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
vancomycin pharmaswiss infusioonilahuse pulber
pharmaswiss ceska republika s.r.o. - vankomütsiin - infusioonilahuse pulber - 1000mg 1tk; 1000mg 10tk
vancomycin pharmaswiss infusioonilahuse pulber
pharmaswiss ceska republika s.r.o. - vankomütsiin - infusioonilahuse pulber - 500mg 10tk
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaktsiinid - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaktsiinid - active immunisation against h5 subtype of influenza a virus.
prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals
glaxosmithkline biologicals s.a. - split gripiviirus, inaktiveeritud, mis sisaldab antigeeni: a / vietnam / 1194/2004 (h5n1) nagu tüvi (nibrg-14) - influenza, human; immunization; disease outbreaks - vaktsiinid - aktiivne immuniseerimine gripiviiruse a viiruse h5n1 alatüübi vastu. see näidustus põhineb immunogenicity andmeid tervisliku teemasid, alates vanusest 18 aastat aastast pärast manustamist kaks annust vaktsiini, mis on valmistatud a/vietnam/1194/2004 nibrg-14 (h5n1) (vt lõik 5. prepandemic gripi vaktsiin (h5n1) (split virion, inaktiveeritud, adjuvanted) glaxosmithkline biologicals 3. 75 µg tuleks kasutada vastavalt euroopa liidu arendus.
vancomycin hospira infusioonilahuse kontsentraadi pulber
hospira uk limited - vankomütsiin - infusioonilahuse kontsentraadi pulber - 1000mg 10ml 1tk
vancomycin hospira infusioonilahuse kontsentraadi pulber
hospira uk limited - vankomütsiin - infusioonilahuse kontsentraadi pulber - 500mg 10ml 1tk
vancomycin kabi 1000mg infusioonilahuse kontsentraadi pulber
fresenius kabi polska sp. z o.o. - vankomütsiin - infusioonilahuse kontsentraadi pulber - 1000mg 10tk; 1000mg 1tk
vancomycin sandoz 500 mg infusioonilahuse pulber
sandoz pharmaceuticals d.d. - vankomütsiin - infusioonilahuse pulber - 500mg 5tk; 500mg 10tk; 500mg 1tk